Empower Advisory Group
AZN icon

Empower Advisory Group’s AstraZeneca AZN Stock Holding History

Empower Advisory Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
5,682
-246
-4% -$46.3K ﹤0.01% 253
2026
Q1 		$1.15M Buy
5,928
+3,707
+167% +$715K ﹤0.01% 236
2025
Q4 		$408K Sell
2,221
-541
-20% -$94.9K ﹤0.01% 364
2025
Q3 		$424K Buy
2,762
+258
+10% +$39K ﹤0.01% 362
2025
Q2 		$350K Sell
2,504
-113
-4% -$15.8K ﹤0.01% 376
2025
Q1 		$385K Buy
2,617
+94
+4% +$13.6K ﹤0.01% 355
2024
Q4 		$331K Buy
2,523
+691
+38% +$96.7K ﹤0.01% 387
2024
Q3 		$285K Sell
1,832
-2,130
-54% -$344K ﹤0.01% 412
2024
Q2 		$618K Sell
3,962
-1,394
-26% -$210K ﹤0.01% 279
2024
Q1 		$726K Sell
5,356
-236
-4% -$31.3K ﹤0.01% 256
2023
Q4 		$753K Buy
5,592
+374
+7% +$48.6K ﹤0.01% 251
2023
Q3 		$707K Buy
5,218
+47
+0.9% +$6.42K ﹤0.01% 254
2023
Q2 		$740K Buy
5,171
+199
+4% +$29.3K ﹤0.01% 256
2023
Q1 		$695K Buy
+4,972
New +$669K ﹤0.01% 270

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Empower Advisory Group's AZN Position: Q2 2026 in Review

Empower Advisory Group reduced its AstraZeneca (AZN) stake by 4.1% in Q2 2026, selling an estimated $46.3K and leaving 5,682 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #253.

Empower Advisory Group first reported a position in AZN in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.15M in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Empower Advisory Group held 5,682 shares of AstraZeneca worth $1.06M as of Q2 2026.
  • Empower Advisory Group sold 246 AstraZeneca shares in Q2 2026, an estimated $46.3K.
  • AstraZeneca made up ﹤0.01% of Empower Advisory Group's portfolio in Q2 2026, its #253 holding.
  • Empower Advisory Group first reported a position in AstraZeneca in Q1 2023 and has held it in 14 quarters since.
  • Empower Advisory Group's AstraZeneca position peaked at $1.15M in Q1 2026.
  • 1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Empower Advisory Group's 13F filing for Q2 2026, filed 12 Aug 2026.